Table 1.
Demographics and clinical information
| Healthy controls | RLS patients | Patients on dopaminergic medication | Untreated patients | Patients on alpha‐2‐delta ligands a | p value b | p value c | |
|---|---|---|---|---|---|---|---|
| Sample size, n | 82 | 82 | 42 | 30 | 10 | — | — |
|
Age, years, mean ± SD |
50.2 ± 10.0 | 51.9 ± 10.8 | 53.1 ± 10.4 | 49.6 ± 11.4 | 53.9 ± 10.3 | 0.320 | 0.736 |
|
Gender, females, n (%) |
43 (52) | 43 (52) | 22 (52) | 14 (47) | 7 (70) | — | — |
|
Disease duration, years, mean ± SD |
— | 16.3 ± 12.9 | 15.2 ± 10.4 | 13.2 ± 10.6 | 21.3 ± 10.9 | 0.447 | 0.104 |
| LEDD medication, median (IQR) | — | 8.8 (0–36) | 30 (18–70) | — | 4.4 (0–64) | — | 0.070 |
| CGI, median (IQR) | — | 3 (3–4) | 3 (3–4) | 3 (3–4) | 4 (2.75–5) | 0.468 | 0.705 |
| IRLS, median (IQR) | — | 14.5 (22–7) | 12 (0–18.75) | 15.50 (9–24.25) | 20.50 (12–31) | 0.127 | 0.048* |
| RLS‐6, mean ± SD | — | 16.0 ± 10.7 | 13.1 ± 9.9 | 17.9 ± 8.7 | 22.7 ± 15.2 | 0.025* | 0.052 |
| Family history | — | 28 | 17 | 9 | 2 | — | — |
| Age of onset | — | 36.5 ± 14.1 | 37.7 ± 14.1 | 36.4 ± 14.5 | 31.2 ± 13.7 | 0.709 | 0.216 |
CGI, clinical global impression (0–7); IQR, interquartile range; IRLS, International Restless Legs Scale (0–40); LEDD, levodopa equivalent daily doses; RLS, restless legs syndrome; RLS‐6, Restless Legs Syndrome‐6 Scale (0–60); SD, standard deviation.
a
Patients on alpha‐2‐delta ligands as mono‐ or polytherapy with dopaminergic medication.
b
The p values shown are for patients on dopaminergic medication against untreated patients.
c
The p values shown are for patients on dopaminergic medication against patients on alpha‐2‐delta ligands as mono‐ or polytherapy with dopaminergic medication.
*
Significant differences.